GlassScriptPhysician profile
Adnan Khalid
NPI 1255369567
$6,792.70
in general payments reported to CMS, 2019-2025
26 companies · $869 in 2025
The $869 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,532 · 2020: $553 · 2021: $213 · 2022: $1,406 · 2023: $1,628 · 2024: $591 · 2025: $869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,533 · Travel and Lodging: $555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,533.34 |
| Travel and Lodging | $554.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,352.34 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Aveir |
| Boston Scientific Corporation | $1,021.64 | 2019-2025 | Avvigo Guidance System, Synergy, Emerge Push |
| Medtronic, INC. | $902.22 | 2022-2023 | Turbohawk, Hawkone |
| Merck Sharp & Dohme LLC | $695.70 | 2022-2025 | Verquvo, Capvaxive |
| Abiomed | $478.47 | 2021-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $403.90 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $335.91 | 2019-2023 | Farxiga |
| Inari Medical, INC. | $315.69 | 2022-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Amgen INC. | $263.44 | 2019-2025 | Repatha, Repatha |
| Medtronic Vascular, INC. | $213.13 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $171.29 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $171.15 | 2020-2022 | |
| Scpharmaceuticals INC. | $94.25 | 2025 | |
| Pfizer INC. | $74.17 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $38.80 | 2024-2025 | Uptravi, Opsumit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $38.07 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $32.38 | 2019-2022 | |
| Akcea Therapeutics, INC. | $29.91 | 2019 | |
| Chiesi USA, INC. | $26.86 | 2019-2022 | |
| Cvrx, INC. | $25.65 | 2022 | |
| Catheter Precision, INC. Fka Ra Medical Systems, INC. | $24.50 | 2019 | |
| Cleerly, INC. | $21.21 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Agepha Pharma Fz LLC | $18.04 | 2024 | Lodoco |
| Lundbeck LLC | $15.85 | 2019 | |
| Ge Healthcare | $15.46 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adnan Khalid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.